摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 5-(4-chlorophenyl)-3,4-dihydro-2,7-dimethyl-4-oxo-5H-pyrano<2,3-d>pyrimidine-6-carboxylate | 119337-29-0

中文名称
——
中文别名
——
英文名称
ethyl 5-(4-chlorophenyl)-3,4-dihydro-2,7-dimethyl-4-oxo-5H-pyrano<2,3-d>pyrimidine-6-carboxylate
英文别名
ethyl 5-(4-chlorophenyl)-2,7-dimethyl-4-oxo-4,5-dihydro-3H-pyrano[2,3-d]pyrimidine-6-carboxylate;ethyl 5-(4-chlorophenyl)-2,7-dimethyl-4-oxo-3,5-dihydropyrano[2,3-d]pyrimidine-6-carboxylate
ethyl 5-(4-chlorophenyl)-3,4-dihydro-2,7-dimethyl-4-oxo-5H-pyrano<2,3-d>pyrimidine-6-carboxylate化学式
CAS
119337-29-0
化学式
C18H17ClN2O4
mdl
——
分子量
360.797
InChiKey
LCRPIYARPZIUJP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    77
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    ethyl 5-(4-chlorophenyl)-3,4-dihydro-2,7-dimethyl-4-oxo-5H-pyrano<2,3-d>pyrimidine-6-carboxylatepotassium carbonate 、 potassium iodide 作用下, 以 乙醇丙酮甲苯 为溶剂, 反应 1.5h, 生成 ethyl 5-(4-chlorophenyl)-2,7-dimethyl-4-oxo-3-[[1-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]triazol-4-yl]methyl]-5H-pyrano[2,3-d]pyrimidine-6-carboxylate
    参考文献:
    名称:
    具有4 H-吡喃并[2,3- d ]嘧啶作为潜在分枝杆菌结核蛋白酪氨酸磷酸酶B抑制剂的1,2,3-1 H-三唑的合成,生物学评估和分子对接研究
    摘要:
    由取代的苯甲醛,丙二腈和乙酰乙酸乙酯在三组分反应中合成了一些杂环,即2-氨基-4 H-吡喃-3-腈。通过在浓硫酸作为催化剂的存在下与乙酸酐进行闭环反应,这些杂环随后被转化为4H-吡喃并[2,3- d ]嘧啶环。在无水碳酸钾存在下,使用炔丙基溴在干燥的丙酮中,进行嘧啶-4-酮环上内酰胺NH键的连续烷基化反应。3-炔丙基-4H-吡喃并[2,3- d ]嘧啶化合物的点击化学已通过与四-O-乙酰基-α- d反应而完成-使用金属-有机骨架[受电子邮件保护]作为无水乙醇中的催化剂的吡喃葡萄糖基叠氮化物。筛选所有合成的1 H- 1,2,3-三唑8a-y的体外结核分枝杆菌蛋白酪氨酸磷酸酶B(MtbPtpB)抑制作用。活性最高的化合物8v,8x和8y的动力学研究表明,它们对MtbPtpB酶具有竞争性抑制作用。详细的结构-活性关系(SAR)的体外和计算机模拟研究表明,Arg63氨基酸与阴离子型对羟基的相互作用是通过
    DOI:
    10.1016/j.bmcl.2018.12.009
  • 作为产物:
    参考文献:
    名称:
    乙基 6-氨基-4-(4-氯苯基)-5-氰基-2-甲基-4H-吡喃-3-羧酸酯的功能化:新型吡喃并[2,3-d]嘧啶衍生物系列的简易合成
    摘要:
    摘要 在此,提出了一系列新的吡喃并[2,3- d ]嘧啶支架的合成。乙基 6-amino-4-(4-chlorophenyl)-5-cyano-2-methyl-4 H -pyran-3-carboxylate 与甲酰胺、甲酸、尿素、硫脲、氨基脲和氨基硫脲反应得到六种新的吡喃[2,3- d]嘧啶衍生物的产率中等至高(48-78%)。吡喃与二硫化碳、氰乙酸乙酯、乙酸酐或氯乙酰氯的酰化和分子内环化导致形成相应的所需双环嘧啶衍生物。氯甲基衍生物通过与吗啉、哌啶或苯胺反应进行亲核取代,得到相应的2-取代嘧啶衍生物,收率良好。
    DOI:
    10.1134/s1070363221070203
点击查看最新优质反应信息

文献信息

  • N-propargylation reaction of substituted 4H-pyrano[2,3-d]pyrimidine derivatives under conventional, ultrasound- and microwave-assisted conditions
    作者:Do Son Hai、Nguyen Thi Thu Ha、Do Tien Tung、Cao Thi Le、Hoang Huu Anh、Vu Ngoc Toan、Hoang Thi Kim Van、Duong Ngoc Toan、Nguyen Thi Kim Giang、Nguyen Thi Thu Huong、Nguyen Dinh Thanh
    DOI:10.1007/s11696-022-02213-0
    日期:2022.8
    substituted 4H-pyrano[2,3-d]pyrimidines were synthesized from corresponding substituted 4H-pyrans by ring-closing reaction with acetic anhydride or acetic acid in the presence of trifluoroacetic acid as catalyst. The successive alkylation reaction of lactam N–H bond on pyrimidine-4-one ring was carried out using propargylic bromide in dry acetonitrile in the presence of anhydrous potassium carbonate. Three
    以相应的取代4 H-喃为原料,以三氟乙酸为催化剂,与乙酸酐乙酸进行闭环反应,合成了一系列取代的4 H-喃并[2,3- d ]嘧啶。在无碳酸存在下,使用炔丙基在无乙腈中进行了嘧啶-4-环上内酰胺 N-H 键的连续烷基化反应。为此目的应用了三个程序,包括功率为 100 W 的 MW 辅助加热条件、50°C 浴中的常规加热条件和 50°C 超声辅助加热条件下。无乙腈用作反应溶剂。N -propargyl-4 H的高产率得到-喃并[2,3- d ]嘧啶生物。化合物6a的单晶X射线结构已被记录下来,该研究有助于确定合成的4 H-喃并[2,3 - d ]嘧啶6a - 6p的N-炔丙基衍生物的结构。
  • Synthesis and in vitro anticancer activity of 4H-pyrano[2,3-d]pyrimidine−1H-1,2,3-triazole hybrid compounds bearing D-glucose moiety with dual EGFR/HER2 inhibitory activity and induced fit docking study
    作者:Nguyen Dinh Thanh、Do Son Hai、Le Thi Huyen、Nguyen Thi Kim Giang、Nguyen Thi Thu Ha、Do Tien Tung、Cao Thi Le、Hoang Thi Kim Van、Vu Ngoc Toan
    DOI:10.1016/j.molstruc.2022.133932
    日期:2023.1
    kinases in comparison with Lapatinib. The resulted docking studies showed that compound 8zc displayed binding mode like Erlotinib on EGFR enzyme and showed good binding energies. Induced fit docking, MM-GBSA calculation, and molecular dynamics simulations were carried out to elucidate the inhibitory potential of compound 8zc against tested enzyme 4HJO. Docking analysis showed that amongst the hydrophilic
    通过相应的2-基-3-基-4 H-喃4a-的闭环反应合成了环的氮原子3上含有炔丙基的多取代的4 H-喃[2,3 - d ]嘧啶6a-zj zj以乙酸酐三氟乙酸为催化剂,然后在超声条件下与溴丙烷烷基化。通过这些N-之间的点击化学合成了一系列 36 种 4 H-喃并[2,3 - d ]嘧啶8a-zj的类似物,其带有d-葡萄糖部分束缚的 1,2,3-三唑生物,其中包括 18 种新衍生物。炔丙基衍生物和过乙酰化d-葡萄糖叠氮化物,以CuNPs@Montmorillonite为催化剂,在DIPEA存在下,t -BuOH/H 2 O中,25℃,超声条件下,20 min。这些化合物对测试的癌细胞(包括 MCF-7、HepG2 和 HeLa)表现出有效的抗癌活性。在测试的化合物中,一些化合物对测试的癌细胞系表现出很强的活性,IC 50 < 4 μM,例如8v、8x、8z、8zc、8zf和8zg对MCF-
  • Harb, Abdel-Fattah A.; Hesien, Abdel-Haleem M.; Metwally, Saoud A., Liebigs Annalen der Chemie, 1989, p. 585 - 588
    作者:Harb, Abdel-Fattah A.、Hesien, Abdel-Haleem M.、Metwally, Saoud A.、Elnagdi, Mohamed Hilmy
    DOI:——
    日期:——
  • HARB, ABDEL-FATTAH A.;HESIEN, ABDEL-HALEEM M.;METWALLY, SAOUD A.;ELNAGDI,+, LIEBIGS ANN. CHEM.,(1989) N, C. 585-588
    作者:HARB, ABDEL-FATTAH A.、HESIEN, ABDEL-HALEEM M.、METWALLY, SAOUD A.、ELNAGDI,+
    DOI:——
    日期:——
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione